Enrique Seoane-Vazquez
Biographic Data
| ID | 5546909 |
|---|---|
| NAME | Enrique Seoane-Vazquez |
| GIVEN NAMES | Enrique |
| FAMILY NAME | Seoane-Vazquez |
| SIGNATURE | SEOANE-VAZQUEZ E |
| AFFILIATIONS | Department of Pharmaceutical Economics and Policy, Chapman University School of Pharmacy, Irvine |
| ORCID | 0000-0002-2763-5685 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2009 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
Analysis of the Gene Therapies Authorized by the United States Food and Drug Administration and the European Medicines Agency
BACKGROUND: Gene therapy, altering the genes inside human cells, has recently emerged as an alternative for preventing and treating disease. Concerns have been expressed about the clinical value and the high cost of gene therapies. OBJECTIVE: This study assessed the characteristics of the clinical trials, authorizations, and prices of gene therapies in the United States and the European Union. RESEARCH DESIGN: We collected regulatory information …
Patent life of antiretroviral drugs approved in the US from 1987 to 2007
This study analyzes the effective patent life of antiretroviral (ARV) new molecular entities (NMEs) approved for marketing in the United States (US) between 1987 and 2007. The study includes all NMEs approved during the study period with at least one patent listed in the Orange Book (OB). Drugs discontinued from the market were excluded from the analysis. Data sources are the US Food and Drug Administration (FDA) and the US Patent and Trademark O…
No prominent works on this page.
Patent life of antiretroviral drugs approved in the US from 1987 to 2007
This study analyzes the effective patent life of antiretroviral (ARV) new molecular entities (NMEs) approved for marketing in the United States (US) between 1987 and 2007. The study includes all NMEs approved during the study period with at least one patent listed in the Orange Book (OB). Drugs discontinued from the market were excluded from the analysis. Data sources are the US Food and Drug Administration (FDA) and the US Patent and Trademark O…
Analysis of the Gene Therapies Authorized by the United States Food and Drug Administration and the European Medicines Agency
BACKGROUND: Gene therapy, altering the genes inside human cells, has recently emerged as an alternative for preventing and treating disease. Concerns have been expressed about the clinical value and the high cost of gene therapies. OBJECTIVE: This study assessed the characteristics of the clinical trials, authorizations, and prices of gene therapies in the United States and the European Union. RESEARCH DESIGN: We collected regulatory information …
Family medicine (2 works) · Food and drug administration (2 works) · Medicine (2 works) · Agency (philosophy) (1 works) · Authorization (1 works) · Bioinformatics (1 works) · Biomedical Ethics and Regulation (1 works) · Business (1 works) · CAR-T cell therapy research (1 works) · Clinical research (1 works)